Post-earnings recap
Reported
Wed, Feb 25, 2026
EPS actual
$-0.69
EPS est.
$-0.53
EPS surprise
-30.68%
1-day move
-0.33%
Protagonist Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. Management's cautious tone suggests they are aware of the hurdles ahead and are taking steps to address them.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.69 | N/A | -30.68% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current market conditions affecting performance. They are focused on strategic initiatives to navigate these challenges.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—